| Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity R Roxburgh, SR Seaman, T Masterman, AE Hensiek, SJ Sawcer, ... Neurology 64 (7), 1144-1151, 2005 | 1056 | 2005 |
| Is it time to target no evident disease activity (NEDA) in multiple sclerosis? G Giovannoni, B Turner, S Gnanapavan, C Offiah, K Schmierer, M Marta Multiple sclerosis and related disorders 4 (4), 329-333, 2015 | 378 | 2015 |
| Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study J Kuhle, G Disanto, R Dobson, R Adiutori, L Bianchi, J Topping, ... Multiple Sclerosis Journal 21 (8), 1013-1024, 2015 | 367 | 2015 |
| T Cell Ig-and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived … M Khademi, Z Illés, AW Gielen, M Marta, N Takazawa, C Baecher-Allan, ... The Journal of Immunology 172 (11), 7169-7176, 2004 | 315 | 2004 |
| Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis D Baker, M Marta, G Pryce, G Giovannoni, K Schmierer EBioMedicine 16, 41-50, 2017 | 256 | 2017 |
| Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis M Marta, Å Andersson, M Isaksson, O Kämpe, A Lobell European journal of immunology 38 (2), 565-575, 2008 | 245 | 2008 |
| Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients MI Leite, E Coutinho, M Lana-Peixoto, S Apostolos, P Waters, D Sato, ... Neurology 78 (20), 1601-1607, 2012 | 232 | 2012 |
| COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases D Baker, CAK Roberts, G Pryce, AS Kang, M Marta, S Reyes, K Schmierer, ... Clinical & Experimental Immunology 202 (2), 149-161, 2020 | 198 | 2020 |
| No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine J Pakpoor, G Disanto, DR Altmann, S Pavitt, BP Turner, M Marta, ... Neuroimmunology & Neuroinflammation 2 (6), e158, 2015 | 143 | 2015 |
| Regulation of autoimmune encephalomyelitis by toll-like receptors M Marta, UC Meier, A Lobell Autoimmunity reviews 8 (6), 506-509, 2009 | 95 | 2009 |
| The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. D Baker, G Pryce, LK James, M Marta, K Schmierer Multiple Sclerosis and Related Disorders, 102279, 2020 | 89 | 2020 |
| Toll‐like receptors in multiple sclerosis mouse experimental models M Marta Annals of the New York Academy of Sciences 1173 (1), 458-462, 2009 | 73 | 2009 |
| Sex effects across the lifespan in women with multiple sclerosis KM Krysko, JS Graves, R Dobson, A Altintas, MP Amato, J Bernard, ... Therapeutic advances in neurological disorders 13, 1756286420936166, 2020 | 71 | 2020 |
| Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring D Hunt, G Giovannoni Practical neurology 12 (1), 25-35, 2012 | 65 | 2012 |
| Protecting people with multiple sclerosis through vaccination S Reyes, M Ramsay, S Ladhani, G Amirthalingam, N Singh, C Cores, ... Practical neurology 20 (6), 435-445, 2020 | 61 | 2020 |
| Biomarker report from the phase II lamotrigine trial in secondary progressive MS–neurofilament as a surrogate of disease progression S Gnanapavan, D Grant, S Morant, J Furby, T Hayton, CE Teunissen, ... PloS one 8 (8), e70019, 2013 | 61 | 2013 |
| The role of HLA-DRB1 alleles on susceptibility and outcome of a Portuguese Multiple Sclerosis population AM Silva, C Pereira, A Bettencourt, C Carvalho, AR Couto, MI Leite, ... Journal of the neurological sciences 258 (1-2), 69-74, 2007 | 61 | 2007 |
| Switching patients at high risk of PML from natalizumab to another disease-modifying therapy G Giovannoni, M Marta, A Davis, B Turner, S Gnanapavan, K Schmierer Practical neurology 16 (5), 389-393, 2016 | 54 | 2016 |
| Viral pathophysiology of multiple sclerosis: A role for Epstein-Barr virus infection? AH Maghzi, M Marta, I Bosca, M Etemadifar, R Dobson, C Maggiore, ... Pathophysiology 18 (1), 13-20, 2011 | 47 | 2011 |
| Disease modifying drugs in multiple sclerosis: mechanisms of action and new drugs in the horizon M Marta, G Giovannoni CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS …, 2012 | 41 | 2012 |
